Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma

Zamtocabtagene autoleucel is currently in clinical development for adults with relapsed or refractory diffuse large B cell lymphoma (DLBCL), not eligible for high-dose chemotherapy and autologous stem cell transplantation. DLBCL is a cancer of B cells (a type of immune cell) and the most common type of fast-growing non-Hodgkin’s lymphoma. In DLBCL, abnormal B cells build up in lymph nodes or other organs. The affected cells divide constantly before they are fully mature and lose their infection-fighting properties, causing vulnerability to infection. Relapsed or refractory DLBCL disease reappears after a period of remission or when the lymphoma becomes non-responsive to treatment. There is a high incidence of disease relapse or becoming refractory after treatment with currently available therapies. Zamtocabtagene autoleucel may be advantageous over other treatment options, especially when patients do not respond to treatment.